NASDAQ · BBNX
Beta Bionics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for BBNX has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.50 | $-0.43 | $-0.54 | 4 |
| Mar 2027 | $-0.55 | $-0.47 | $-0.62 | 2 |
| Jun 2027 | $-0.50 | $-0.45 | $-0.54 | 2 |
| Sep 2027 | $-0.63 | $-0.44 | $-0.81 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · Zacks · Fintel- The Motley Fool · Oct 28, 1:43 AM EDTBeta Bionics (BBNX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Oct 27, 8:04 PM EDTBeta Bionics Q3 Earnings Call HighlightsBeta Bionics (NASDAQ:BBNX) reported third-quarter net sales of $35.5 million, up about 30% from a year earlier, as new patient starts and recurring revenue from its pharmacy-channel user base supported growth. The company also raised the lower end of its full-year revenue outlook
- Zacks · Oct 27, 4:15 PM EDTBeta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue EstimatesBeta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +1.89% and +0.96%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 22, 8:58 AM EDTIQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should KnowIQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.
- Zacks · Oct 20, 9:00 AM EDTBeta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Beta Bionics, Inc. (BBNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 1, 9:34 PM EDTBeta Bionics Consensus Price Target Raised 14.64% to $23.75The average one-year price target for Beta Bionics (NASDAQGM:BBNX) has been revised to $23.75 / share. This is an increase of 14.64% from the prior estimate of $20.72 dated September 11, 2026. These figures represent aggregate analyst targets compiled from multiple sources and d
- Zacks · Sep 29, 10:06 AM EDTBeta Bionics Stock Down Despite iLet-Eversense 365 Integration DealBBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.
- RTTNews · Sep 18, 10:44 AM EDTWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) – Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
- Zacks · Sep 17, 12:01 PM EDTBeta Bionics Stock Surges on FDA Clearance for Mint Patch PumpBBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
- Zacks · Sep 17, 6:21 AM EDTBeta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?Beta Bionics, Inc. (BBNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- RTTNews · Sep 16, 3:17 AM EDTBeta Prices $150 Mln Public Offering Ahead Of Mint Commercialization; Stock Down(RTTNews) – Beta Bionics, Inc. (BBNX), a commercial-stage medical device company focused on diabetes management, announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expected to generate approximately $150 million in gross proceeds.
- RTTNews · Sep 14, 8:12 AM EDTBeta Bionics: FDA Clearance Of Mint Sets Stage For 2027 Patch Pump Launch(RTTNews) – Beta Bionics, Inc. (BBNX) announced FDA clearance of Mint, its new patch pump featuring a reusable and disposable architecture, while unveiling 3D Intelligence, its next-generation insulin dosing algorithm submitted to the FDA through a 510(k) application.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Beta Bionics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.